(Q44839961)

English

Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a

scientific article published in April 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ingolf Schiefke

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Chris Klecker

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Melanie Maier

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Ute Oesen

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Gunnar Etzrodt

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Andrea Tannapfel

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Uwe G Liebert

7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Frieder Berr

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2004

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Liver International

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

98-104

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.0889.X

21 January 2018

Identifiers

10.1111/J.1478-3231.2004.0889.X

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

release_zmmjangurbcjha6px6x5uv7klq

1 reference

https://api.fatcat.wiki/v0/release/zmmjangurbcjha6px6x5uv7klq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44839961&oldid=2050077755"